Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555990 |
US |
2 | |
Device failure, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 2 | 26556056 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Underdose, Product complaint, |
||||
BELIMUMAB, |
||||
| 3 | 26557350 |
US |
70 | 2 |
Exposure via skin contact, |
||||
ALIROCUMAB, |
||||
| 4 | 26557437 |
US |
72 | 1 |
Abdominal pain upper, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 5 | 26557467 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 6 | 26557474 |
US |
54 | 1 |
Injection site vesicles, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, BUDESONIDE, LISINOPRIL, |
||||
| 7 | 26557490 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 8 | 26557495 |
US |
79 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 9 | 26557555 |
US |
||
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 10 | 26557586 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 11 | 26557974 |
US |
75 | 2 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
INSULIN GLARGINE, |
||||
| 12 | 26558024 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 13 | 26558030 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 14 | 26558043 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 15 | 26558779 |
US |
64 | 2 |
Accidental exposure to product, Incorrect disposal of product, Wrong technique in device usage process, Exposure via skin contact, Incorrect dose administered by device, Device difficult to use, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, ADALIMUMAB, |
||||
| 16 | 26560040 |
US |
61 | 2 |
Blindness, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 17 | 26560238 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 18 | 26560286 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 19 | 26560291 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 20 | 26560695 |
US |
67 | 2 |
Chronic obstructive pulmonary disease, Weight decreased, Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Wrong technique in device usage process, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 21 | 26560760 |
US |
56 | 2 |
Accidental exposure to product, Drug dose omission by device, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 22 | 26550026 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 23 | 26550046 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, LATANOPROST, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 24 | 26550066 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 25 | 26550070 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 26 | 26550151 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 27 | 26550246 |
US |
2 | |
Blister, Condition aggravated, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FISH OIL, GARLIC, SUMATRIPTAN, LISINOPRIL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PIMECROLIMUS, |
||||
| 28 | 26550760 |
US |
2 | |
Eye pain, Exposure via skin contact, Accidental exposure to product, |
||||
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE, |
||||
| 29 | 26551412 |
US |
91 | 2 |
Injection site haemorrhage, Exposure via skin contact, Incorrect route of product administration, Wrong technique in device usage process, Accidental exposure to product, Underdose, |
||||
MEPOLIZUMAB, |
||||
| 30 | 26552957 |
US |
56 | 2 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, Intentional dose omission, |
||||
EVOLOCUMAB, NITROGLYCERIN, EPINEPHRINE, |
||||
| 31 | 26555218 |
US |
87 | 2 |
Exposure via skin contact, Needle issue, Accidental exposure to product, |
||||
ABATACEPT, NAPROXEN SODIUM, NAPROXEN SODIUM TABLET, ZOLPIDEM TARTRATE, CELECOXIB, FLUTICASONE PROPIONATE, SACCHAROMYCES CEREVISIAE, LORAZEPAM, LEVOTHYROXINE SODIUM, |
||||
| 32 | 26549133 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 33 | 26549215 |
US |
60 | 1 |
Injection site mass, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 34 | 26549254 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 35 | 26549270 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 36 | 26549594 |
US |
77 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 37 | 26549606 |
US |
8 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 38 | 26549658 |
US |
66 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
DUPILUMAB, |
||||
| 39 | 26549802 |
US |
46 | 2 |
Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Product communication issue, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 40 | 26549807 |
US |
60 | 2 |
Skin discolouration, Accidental exposure to product, Exposure via skin contact, |
||||
BRIMONIDINE TARTRATE, |
||||
| 41 | 26546946 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 42 | 26546962 |
US |
2 | |
Product delivery mechanism issue, Overdose, Exposure via skin contact, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 43 | 26547139 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 44 | 26547279 |
US |
54 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 45 | 26547327 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 46 | 26547330 |
US |
55 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 47 | 26547379 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 48 | 26547819 |
US |
45 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 49 | 26547905 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 50 | 26547943 |
US |
62 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 51 | 26548246 |
US |
63 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 52 | 26548320 |
US |
2 | |
Erythema, Eye swelling, Exposure via skin contact, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 53 | 26548396 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 54 | 26548399 |
US |
42 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, FAMOTIDINE, |
||||
| 55 | 26548535 |
US |
12 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 56 | 26548540 |
US |
22 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 57 | 26548543 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 58 | 26548561 |
US |
93 | 1 |
Pruritus, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 59 | 26548562 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 60 | 26548577 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 61 | 26548597 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, ALBUTEROL SULFATE, DEUTETRABENAZINE, BIOTIN, EZETIMIBE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, GABAPENTIN, EMPAGLIFLOZIN, MELATONIN, PROPRANOLOL HYDROCHLORIDE, TIZANIDINE, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 62 | 26548615 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 63 | 26548622 |
US |
74 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 64 | 26548669 |
US |
||
Scratch, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 65 | 26548717 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 66 | 26548721 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 67 | 26548736 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 68 | 26548740 |
US |
64 | 2 |
Injection site mass, Injection site swelling, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, GABAPENTIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, HYOSCYAMINE SULFATE, MONTELUKAST SODIUM, MONTELUKAST, |
||||
| 69 | 26548761 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
DUPILUMAB, |
||||
| 70 | 26548779 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 71 | 26548827 |
US |
55 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
MEPOLIZUMAB, TIRZEPATIDE, |
||||
| 72 | 26545490 |
US |
53 | 2 |
Accidental exposure to product, Exposure via skin contact, Wrong technique in device usage process, Device leakage, Incorrect dose administered by device, |
||||
SOMATROPIN, |
||||
| 73 | 26546062 |
US |
33 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 74 | 26546070 |
US |
85 | 2 |
Dyspnoea, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 75 | 26546078 |
US |
70 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 76 | 26546085 |
US |
80 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 77 | 26546092 |
US |
22 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 78 | 26546101 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 79 | 26546104 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 80 | 26546119 |
US |
57 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
BELIMUMAB, |
||||
| 81 | 26536059 |
US |
63 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 82 | 26536060 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 83 | 26536373 |
US |
47 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Incorrect dose administered by device, Accidental exposure to product, |
||||
MEPOLIZUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, IPRATROPIUM BROMIDE, |
||||
| 84 | 26537943 |
US |
||
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 85 | 26537987 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 86 | 26538058 |
US |
48 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 87 | 26538062 |
US |
38 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 88 | 26538086 |
US |
73 | 2 |
Accidental exposure to product, Drug ineffective, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 89 | 26538103 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 90 | 26538104 |
US |
36 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 91 | 26538113 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 92 | 26538195 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 93 | 26538212 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 94 | 26538428 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, Product storage error, |
||||
DUPILUMAB, |
||||
| 95 | 26538429 |
US |
78 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 96 | 26538467 |
US |
73 | 1 |
Road traffic accident, Mobility decreased, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 97 | 26538468 |
US |
71 | 2 |
Injection site pain, Injury associated with device, Product storage error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 98 | 26539923 |
US |
24 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 99 | 26540924 |
US |
83 | 2 |
Influenza, Dysphonia, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 100 | 26540945 |
US |
86 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28